Athanasios joined us in 2024 as our Knowledge Transfer Partnership (KTP) Associate. This is a collaborative project between RoukenBio and the University of the West of Scotland, supporting the development of a wide range of 3D models for our customers. Athanasios works together with our CSO and the Innovation team to develop tissue-based explant, tumoroid, and organoid models.
Following his PhD in Gastric Premalignant Lesions, Athanasios has had a varied career in academia and industry. He is passionate about advancing the understanding and treatment of cancer and other diseases through innovative and cutting-edge technologies.
Resources
Insights
4 September 2026
|7 min read
RoukenBio’s human donor-derived air-liquid interface (ALI) asthma model recreates key features of Type 2 airway inflammation, including mucus production and epithelial remodelling. Discover how this translational platform supports target validation, biomarker analysis and therapeutic evaluation in asthma drug discovery.
Research Posters
17 August 2026
|4 min read
This research poster presents a high-throughput, patient-derived colorectal cancer tumoroid platform incorporating autologous fibroblasts and tumour-infiltrating lymphocytes. By combining genomic, gene-expression and drug-response data, the model captures patient-specific tumour heterogeneity and supports translational drug discovery, predictive biomarker identification and immunotherapy research.
Insights
5 August 2026
|5 min read
Explore how RoukenBio’s patient-derived ex vivo IBD model preserves key tissue compartments to support more clinically relevant therapeutic testing for Crohn’s disease and ulcerative colitis.
